Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
35.93
+0.12 (0.34%)
At close: Sep 28, 2026, 4:00 PM EDT
35.61
-0.32 (-0.89%)
Pre-market: Sep 29, 2026, 5:31 AM EDT
Castle Biosciences Employees
Castle Biosciences had 1,002 employees as of June 30, 2026. The number of employees increased by 204 or 25.56% compared to the same quarter last year.
Employees
1,002
Change
204
Growth
25.56%
Revenue / Employee
$356,565
Profits / Employee
-$19,376
Market Cap
1.10B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 1,002 | 204 | 25.56% | 1,002 | 0 |
| Mar 31, 2026 | 942 | 158 | 20.15% | 942 | 0 |
| Dec 31, 2025 | 883 | 122 | 16.03% | 883 | 0 |
| Sep 30, 2025 | 823 | 113 | 15.92% | 823 | 0 |
| Jun 30, 2025 | 798 | 95 | 13.51% | 798 | 0 |
| Mar 31, 2025 | 784 | 146 | 22.88% | 784 | 0 |
| Dec 31, 2024 | 761 | 151 | 24.75% | 761 | 0 |
| Sep 30, 2024 | 710 | 123 | 20.95% | 710 | 0 |
| Jun 30, 2024 | 703 | 121 | 20.79% | 703 | 0 |
| Mar 31, 2024 | 638 | 95 | 17.50% | 638 | 0 |
| Dec 31, 2023 | 610 | 67 | 12.34% | 610 | 0 |
| Sep 30, 2023 | 587 | 70 | 13.54% | 587 | 0 |
| Jun 30, 2023 | 582 | 100 | 20.75% | 582 | 0 |
| Dec 31, 2022 | 543 | 198 | 57.39% | 542 | 1 |
| Sep 30, 2022 | 517 | 206 | 66.24% | 517 | 0 |
| Jun 30, 2022 | 482 | 190 | 65.07% | 482 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Myriad Genetics | 2,700 |
| NeoGenomics | 2,500 |
| OPKO Health | 2,275 |
| Fulgent Genetics | 1,315 |
| GeneDx Holdings | 1,300 |
| CareDx | 765 |
| Veracyte | 755 |
| Adaptive Biotechnologies | 624 |
CSTL News
- 23 hours ago - Castle Biosciences: Study shows TissueCypher test changed management - TheFly
- 23 hours ago - New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus - PRNewsWire
- 4 days ago - New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™ - PRNewsWire
- 6 days ago - Castle Biosciences to open new laboratory facility in Scottsdale, Arizona - TheFly
- 6 days ago - Castle Biosciences to Open New Laboratory Facility in Scottsdale - PRNewsWire
- 7 days ago - Castle Biosciences management to meet with BTIG - TheFly
- 13 days ago - Castle Biosciences Transcript: 2026 Global Healthcare Conference - Transcripts
- 13 days ago - Castle Biosciences’ TissueCypher shows improvement in Barrett’s esophagus - TheFly